The aim of this study was to formulate and evaluate microsphere based depot type parenteral sustained release formulation of diclofenac sodium (DFS). Drug was formulated in the form of microspheres, using varying proportion of ethylcellulose (EC) as the retardant material to extend the release, by phase separation-coacervation technique. The in vitro release pattern of the designed formulations was studied using modified Franz diffusion cell. In vivo pharmacodynamic study was carried out by determining the index of analgesia (increase in response time to thermal stress as percentage of basal response time). Tail flick method was employed to measure both the degree of analgesia and its duration of action. The prepared microspheres were white, free flowing, and spherical in shape with a mean particle size of 50 pm. In vitro release study of the micro-spheres in aqueous media was found to extend the release of DFS beyond 24 hours with DFS and EC ratio 1:3. The plot of log percentage remaining to be released vs. time gave a linear relationship indicating first-order release kinetics. The in vitro release rate constant (K,) for different microspheres varied between 0.1448 h i ' and 0.0256 hr-'. A good correlation was obtained between K, and proportion of EC in the microspheres. In vivo pharmacodynamic studies indicated that the duration of analgesic action is prolonged beyond 24 hrs in case of microsphere products of 1:3 ratio of DFS to EC, whereas administration of marketed parenteral preparation showed activity only up to 1 lhrs. Also, a good correlation was obtained between analgesic activity in vivo and cumulative percentage of drug release from the formulations.
Introduction
DFS, an effective non-steroidal anti-inflammatory and analgesic drug with its low oral bioavilability (60%), short plasma half-life (1.1 -1.8 hrs), and low dose (25-75 mg thrice daily) is an ideal candidate for the formulation of parenteral sustained release drug delivery system in the management of acute and chronic pain and traumatic conditions'". A good amount of work have been reported in the literature on the development of oral sustained release drug delivery system for Diclofenac Sodium (DFS), including the work by our group3". However, very little work has been reported on the development of parenteral sustained release formulation. The efficacy of dosage regimen in such conditions depend on the ability of the parenterally administered sustained release formulation to provide an initial burst release of drug to facilitate rapid onset of action and then maintain a constant plasma drug level for prolonged period of time. Such a formulation will thereby decrease the dosing frequency, alleviate pain and suffering for longer duration and at the same time avoid systemic accumulation of the drug and related side effects6.
Increased need for patient compliance, especially in chronic pain or postoperative conditions, and improving the therapeutic eficacy of the drug suggest the need for sustained release parenteral drug delivery system for DFS.
Sustained release parenteral formulations of DFS have been attempted at by only few workers and are not simple. Various techniques which have been utilized for this purpose include multiple emulsion system7, poly-lactic-co-glycolic acid copolymer microcapsules8, and in situ gel forming systemsg. Ethyl cellulose (EC) has been widely used for the microencapsulation of a number of water-soluble drugs to retard the release rate or to improve the stability5* ''-I3.
In the present study microsphere based depot type formulations were designed for DFS, using varying proportion of EC as the retardant material, by phase separation coacervation technique. Physical characteristics, micromeritics, and in vitro release studies were carried out to evaluate the release characteristics of DFS from these microsphere-based formulations. In vivo pharmacodynamic studies were carried out on animal (albino rat) model to measure the degree and sustained nature of the analgesia produced by tail-flick method (analgesiometer), wherein, the index of analgesia was calculated as increase in response time as percentage of basal response time and compared with conventional market preparation. A regression analysis was performed between index of analgesia and cumulative percentage drug released in vitro, up to time for 60% of drug release. 
Results and discussions
Supplied DFS characterized by various official tests of identification" and analyzed by UV spectrophotometric method passed the tests of identification and analysis. Studies on effect of various formulation excipients like ethyl cellulose and cyclohexane on the stability of DFS suggest that the formulation additives, in the concentration used, did not affect the stability and UV absorbency profile of DFS. Physical characteristics and drug content per gram of formulated microspheres are presented in Table 1 . The microspheres were white, free flowing and spherical in shape. The mean particle size varied between 49.94 pm to 52.72 pm for different formulations of DFS-EC microspheres ( Table 1 ). The drug content per gram of the microspheres, as expected, decreased as proportion of the EC was increased. In vitro release study of the microspheres, performed in phosphate buffer of pH 6.8 showed that the duration of DFS release was extended beyond 24 hrs in case of DMS3 whereas in DMSl and DMS2 the release were much faster. The plot of log percentage remaining to be released vs. time gave a linear relationship ( Figure 1 ) suggesting first-order release kinetics of DFS from the EC microspheres. The in vitro release rate constant (K,), as obtained from the slope of the plot and enlisted in Table 1 , varied between 0.1448 hr-' (DMS1) and 0.0256 h-' (DMS3).
Since the EC barrier layer is insoluble in water, the release of the drug probably occurred through partitioning andlor diffusion. Increasing the proportion of EC slowed the rate of release. About 
Experimental

Materials
Diclofenac sodium I.P. was obtained as gift sample from Torrent Pharmaceuticals Ltd., Ahmedabad, India. Ethyl cellulose and all other chemicals and reagents used in the study were of pharmaceutical or analytical grade.
Characterization of bulk drug
Bulk drug was characterized by various official tests of identification and analyzed by UV spectrophotometric method (Jasco, UV-Vis spectrophotometer; model -7800) at 276 nm in aqueous medium. Effect of various excipients like ethyl cellulose and cyclohexane on the stability and analysis of DFS was also studied.
Preparation of microspheres
Phase separation-coacervation method was employed to formulate microspheres of DFS 
Physical characterization of the microspheres
The microspheres prepared were studied for appearance and size distribution using optical microscopy. The drug content in the microspheres was determined by dissolving accurately weighed amount of the formulation in little amount (4 mL) of methanol to dissolve the EC coat.
To this 20-25 mL of triple distilled water was added and then the solution heated to evaporate the methanol. The solution was filtered to remove insoluble EC, suitably diluted and analyzed by W spectrophotometric method at 276 nm.
In vitro release study
The in vitro release from the designed formulations was studied using modified Franz 
Data analysis
All values presented in this study are average of replicate experiments at the same time points. Least square regression equations and the correlation coefficients were calculated using Microsoft Office 2000, Excel package. Difference in in vitro release as well as in vivo pharmacodynamic profile of various designed formulations were tested stati~ticall~'~ using oneway analysis of variance and Tukey's multiple range test at p < 0.05.
